Boston Scientific (BSX) Liabilities and Shareholders Equity (2009 - 2026)

Boston Scientific (BSX) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $44.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 10.49% year-over-year to $44.4 billion; the trailing twelve-month figure through Mar 2026 stood at $172.3 billion (up 11.36% YoY), and the FY2025 full-year result was $43.7 billion, up 10.86% from the prior year.
• Liabilities and Shareholders Equity advanced to $44.4 billion in Q1 2026, from $43.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $44.4 billion in Q1 2026 to a low of $31.9 billion in Q3 2022.
• A 5-year average of $37.0 billion and a median of $36.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity advanced 0.22% in 2022 and grew 12.16% in 2025, its largest moves.
• Tracing BSX's Liabilities and Shareholders Equity over 5 years: stood at $32.5 billion in 2022, then increased by 8.21% to $35.1 billion in 2023, then advanced by 12.12% to $39.4 billion in 2024, then advanced by 10.86% to $43.7 billion in 2025, then increased by 1.55% to $44.4 billion in 2026.
• Business Quant data shows BSX's Liabilities and Shareholders Equity at $44.4 billion in Q1 2026, $43.7 billion in Q4 2025, and $42.7 billion in Q3 2025.